3 completed, 1 active not recruiting, 1 enrolling by invitation, 1 not yet recruiting. 3 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 1, Enrolling by invitation 1, Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Bullous Pemphigoid (BP): new trials by email Literature Review of Bullous Pemphigoid (BP) trials Research Report on Bullous Pemphigoid (BP)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Association Between Disease Severity and Clinical, Histopathological, and Eosinophilic Markers in Patients With Bullous Pemphigoid (BP-EPIC) Bullous Pemphigoid (BP) | Active not recruiting | Istanbul Training and Research Hospital | 50 | 2026-05-04 | 2026-06-16 | |
| Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid Stapokibart injection, Placebo - Bullous Pemphigoid (BP) | Phase 3 | Not yet recruiting | Chengdu Kangnuoxing Biopharma,Inc. | 200 | 2025-11-11 | 2025-10-07 |
| Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial) RAY121 - Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP) | Phase 1 | Enrolling by invitation | Chugai Pharmaceutical | 144 | 2024-12-09 | 2026-07-17 |
| Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) RAY121 - Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP) | Phase 1 | Recruiting | Chugai Pharmaceutical | 144 | 2024-08-19 | 2026-07-22 |
| Prevalence of Sleep Disturbances in Bullous Pemphigoid Patients. Prevalence of sleep disturbances in patients with bullous pemphigoid, Prevalence of sleep disturbances in healthy volunteers without bullous pemphigoid - Bullous Pemphigoid (BP) | Completed | University Hospital, Rouen | 122 | 2020-08-04 | 2025-09-23 | |
| rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects rVA576 - Bullous Pemphigoid (BP) | Phase 2 | Completed | AKARI Therapeutics | 9 | 2018-09-25 | 2025-04-22 |
| Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disorders BIV009, Placebo - Bullous Pemphigoid (BP), Cold Agglutinin Disease (CAD) | Phase 1 | Completed | Bioverativ, a Sanofi company | 122 | 2015-07-13 | 2022-04-25 |
Pemphigoid, Bullous (7) · Antiphospholipid Syndrome (2) · Behcet Syndrome (2) · Dermatomyositis (2) · Purpura, Thrombocytopenic, Idiopathic (2) · Anemia, Hemolytic, Autoimmune (1) · Eosinophilia (1) · Kidney Failure, Chronic (1)
Autoimmune Diseases (7) · Immune System Diseases (7) · Skin Diseases (7) · Skin Diseases, Vesiculobullous (7) · Skin and Connective Tissue Diseases (7) · Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Blood Coagulation Disorders (2) · Blood Platelet Disorders (2) · Cardiovascular Diseases (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Connective Tissue Diseases (2) · Cytopenia (2)
Saline Solution (1)
Chugai Pharmaceutical (2) · AKARI Therapeutics (1) · Bioverativ, a Sanofi company (1) · Chengdu Kangnuoxing Biopharma,Inc. (1) · Istanbul Training and Research Hospital (1) · University Hospital, Rouen (1)
Austria (3) · France (3) · Germany (3) · Netherlands (3) · Turkey (Türkiye) (3) · Australia (2) · Bulgaria (2) · Canada (2) · Croatia (2) · Czechia (2) · Hungary (2) · Italy (2) · Japan (2) · Norway (2) · Poland (2)
Ayse Esra Koku Aksu, Prof.Dr. (1) · Hang Li, Chief physician (1)
PMID 27716293, PMID 28926521, PMID 28980446, PMID 30559259, PMID 35507334, PMID 38995690
2014 (1)